Disease · MONDO_0005129
Comparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 16 of 16
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| T2380 vs Reference Group: serious adverse events | 4 of 295 | 6 of 296 | 591 | NCT02101359 | Trial comparisons |
| Chloroprocaine 3% vs Tetracaine 0.5%: deaths from any cause | 0 of 167 | 0 of 171 | 338 | NCT04685538 | Trial comparisons |
| Chloroprocaine 3% vs Tetracaine 0.5%: serious adverse events | 0 of 167 | 0 of 171 | 338 | NCT04685538 | Trial comparisons |
| T-Pred vs Pred-Forte: serious adverse events | 1 of 162 | 1 of 162 | 324 | NCT00854061 | Trial comparisons |
| ISV-303 vs Vehicle: serious adverse events | 1 of 170 | 1 of 85 | 255 | NCT01808547 | Trial comparisons |
| ISV-303 vs Vehicle: serious adverse events | 0 of 169 | 1 of 85 | 254 | NCT01576952 | Trial comparisons |
| ISV-303 vs Vehicle: Ocular Inflammation | 96 of 168 | 16 of 85 | 253 | NCT01576952 | Trial comparisons |
| ISV-303 vs Vehicle: Ocular Inflammation | 64 of 168 | 19 of 85 | 253 | NCT01808547 | Trial comparisons |
| Bromfenac vs Placebo: Number of Participants That Are Pain Free | 51 of 63 | 46 of 63 | 126 | NCT00703781 | Trial comparisons |
| Bromfenac vs Placebo: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero | 28 of 63 | 20 of 63 | 126 | NCT00703781 | Trial comparisons |
| Bromfenac vs Placebo: serious adverse events | 2 of 61 | 0 of 61 | 122 | NCT00703781 | Trial comparisons |
| OMS302 vs Phenylephrine HCl: Safety as Measured by Treatment-emergent Adverse Events, the Number of Affected Patients/at Risk (%) and the Number of Events. | 15 of 32 | 18 of 40 | 72 | NCT02132312 | Trial comparisons |
| OMS302 vs Phenylephrine HCl: deaths from any cause | 0 of 32 | 0 of 40 | 72 | NCT02132312 | Trial comparisons |
| OMS302 vs Phenylephrine HCl: serious adverse events | 2 of 32 | 0 of 40 | 72 | NCT02132312 | Trial comparisons |
| Dexamethasone Phosphate Ophthalmic vs 100 mM Sodium Citrate Buffer: Percentage of Subjects With AC Cell Count of Zero on Day 7 | 3 of 23 | 2 of 22 | 45 | NCT01602068 | Trial comparisons |
| Dexamethasone Phosphate Ophthalmic vs 100 mM Sodium Citrate Buffer: serious adverse events | 0 of 23 | 3 of 22 | 45 | NCT01602068 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005129/comparisons